ondansetron clinical trial formulation + ondansetron marketed formulation
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Nausea and Vomiting
Conditions
Chemotherapy-Induced Nausea and Vomiting
Trial Timeline
Jun 1, 2004 โ Sep 1, 2004
NCT ID
NCT00972595About ondansetron clinical trial formulation + ondansetron marketed formulation
ondansetron clinical trial formulation + ondansetron marketed formulation is a phase 1 stage product being developed by Merck for Chemotherapy-Induced Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT00972595. Target conditions include Chemotherapy-Induced Nausea and Vomiting.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00972595 | Phase 1 | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Nausea and Vomiting